If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
118
results.
Updated on
24/12/2025 [07:13:00]
Results 50 to 75 of 118
Absstract of: US2025352527A1
Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.
Absstract of: US2025352640A1
The invention is situated in the field of vaccination therapy. More specifically, the invention relates to a multi-epitope construct comprising nucleic acid sequences encoding peptides or functional variants and fragments thereof derived from a coronavirus. The invention further relates to a combination, polypeptides, or pharmaceutical composition for use in the treatment or prevention a coronavirus in a subject; in particular the SARS-COV-2 virus.
Absstract of: US2025352558A1
The present invention relates generally to a method of formulation of cannabidiol (CBD) a potential anti-inflammatory drug derived from lemon peel (d-limonene). More, particularly, the present invention relates to the enhancement of lipid soluble CBD into water soluble form in order to improve the formulation of the active component while apply in human for medication. The present invention further provides the therapeutic application of the new formulation which either neutralize and/or decreases the capability of the production of cytokines by activated immune cells during inflammatory process and hence alleviate the sufferings of illness like COVID-19 caused by SARSCOV2.
Absstract of: US2025352517A1
An object is to provide a composition for treatment or prevention of an infection caused by SARS-COV-2 (COVID-19). Based on establishment of a screening method for drugs having an inhibitory activity against proteases of SARS-COV2, and discovery of an inhibitory activity of selenoneine against the proteases of SARS-COV2, a composition for treatment or prevention of COVID-19, which composition includes selenoneine, is provided.
Absstract of: US2025345307A1
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus SARS-CoV, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, the virus and its mutant forms that cause COVID-19, Middle East respiratory syndrome coronavirus MERS-CoV), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
Absstract of: US2025347699A1
This disclosure relates to a method of expressing the receptor-binding domain (RBD) region of the coronavirus SARS-CoV-2 Spike protein in a highly native form that is strongly reactive to natural antibodies induced upon SARS-CoV-2 infection or vaccination of humans and that more efficiently binds the angiotensin-converting enzyme 2 (ACE2) receptor. This method fuses the RBD to the C-terminus of an N-terminal fragment of the gp70 protein (the surface protein (SU) of the Friend57 strain of murine leukemia viruses). This method of expression enhances the native folding of the RBD and increases its recognition by antibodies present in immune sera and its ability to interact with the ACE2 receptor. Further disclosed are methods of using this form of RBD for various purposes.
Absstract of: AU2024271182A1
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Absstract of: US2025346615A1
Glycerophosphoinositol (GPI) is used in preventing and treating COVID-19 infections. An environmentally sustainable method is for obtaining glycerophosphoinositol. In particular, a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, includes in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. Moreover, glycerophosphoinositol is used in preventing and treating a COVID-19 syndrome.
Absstract of: US2025345408A1
The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.
Absstract of: WO2025234971A1
This invention discloses the novel Formula (I) 4,4'-disulfanediylbis(N-(4-morpholinobenzylidene)aniline) compound for use in the treatment of diseases caused by viruses, particularly Herpes simplex virus-1, human Poliovirus, Adenovirus and Bovine coronavirus, the form of this compound in a structure conjugated with G- GQDs (glutathione-functionalised graphene quantum dots) and the synthesis method thereof.
Absstract of: US2025344786A1
Disclosed herein are protective apparatuses for minimizing the risk of transmission of SARS-CoV-2 and other infectious diseases between individuals in close proximity to one another. Said apparatuses may comprise a receiving component comprising a first aperture comprising a series of flanges; as well as a substantially transparent shield component. Protective apparatuses of the present disclosure may be used to protect dentists and other healthcare workers from transmission of infectious agents and likewise may be used to protect patients in the same manner. Also disclosed herein are systems comprising such protective apparatuses installed to a substantially cylindrical suctioning device such as a vacuum hose or operatively attached to an articulating mechanical arm. Also disclosed herein are methods of using such protective apparatuses and systems to mitigate the risk of transmission of infectious diseases between, without limitation, patients and healthcare workers treating such patients.
Absstract of: US2025345415A1
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
Absstract of: US2025345413A1
An immunogenic subunit vaccine antigen which comprises at least two receptor-binding domains (RBDs) of the spike (S) protein of SARS-CoV-2 which are fused to a heterologous immunogenic carrier protein, wherein each of said at least two RBDs has a folded structure in an accessible conformation to bind the human angiotensin-converting enzyme 2 (ACE2) receptor protein.
Absstract of: WO2025235945A1
The present disclosure provides methods of treating viral infections (e.g., SARS-CoV-2 infection) comprising administration of a fusion inhibitor.
Absstract of: PL448505A1
Przedmiotem zgłoszenia jest kompozycja, sposób jej przygotowania oraz zastosowanie do zapobiegania zakażeniom koronawirusami, zwłaszcza SARS-CoV-2. Kompozycja w postaci wodnego koloidu zawiera w składzie 10% ektoinę oraz 0,1% hydroksyfuleren C60(OH)40 zmieszane w stosunku objętościowym 2:1. Preparat nanosi się na komórki nabłonka nosa narażone na kontakt z białkiem otoczki wirusa. Celem nanoszenia preparatu jest utworzenie stabilnej i przepuszczającej powietrze powłoki ochronnej, która wykazuje właściwości barierowe i pułapkowania w płaszczu wodnym i wirusobójcze wobec koronawirusów.
Absstract of: EP4647092A2
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called "long haul" symptoms of COVID-19 or similar disease. The present invention directly benefits these patients by providing lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-CoV-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-CoV-2-derived glycoproteins and/or other biological molecules, including microRNAs, from the circulatory system, thereby reducing the severity of the disease or symptoms thereof. For patients severely affected by or at high risk for severe COVID-19 disease due to a SARS-CoV infection, the devices and methods of the present invention can be used to reduce time spent on mechanical ventilators, reduce the likelihood of cardiac complications, reduce the likelihood of multiorgan failure, reduce the likelihood of acute kidney disease, sepsis and/or other complications. Also disclosed herein are devices and methods for reducing the levels of b
Absstract of: KR102879758B1
본 발명은 제2형 중증급성호흡기증후군 코로나바이러스 스파이크 단백질에 대한 다중 에피토프를 포함하는 코로나19 백신 조성물에 관한 것이다.
Absstract of: US2025340957A1
An oligonucleotide, having a 5′ terminus and a 3 terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:60 and SEQ ID NO:77.
Absstract of: WO2025227322A1
Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and/or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.
Absstract of: WO2025231018A2
Disclosed herein are capped RNA molecules comprising one or more modified nucleotides at position +3 or higher with reference to a 5' terminus of the RNA molecule, and methods of making the same. The capped RNA molecules may be made by ligating a 5'-capped modified RNA oligonucleotide to the 3' terminus of an RNA molecule. Also provided are compositions comprising one or more of the capped RNA molecules provided herein, and methods of using said compositions for therapeutic applications, such as in the treatment or prevention of a disease in a subject, such as SARS-CoV-2.
Absstract of: US2025339502A1
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
Absstract of: US2025341521A1
The present invention provides a novel method for the production of truly fully human monoclonal antibodies against SARS-CoV-2 using isolated human blood cells. These antigens may include but are not limited to peptide sequences found in envelope or spike proteins of SARS-CoV-2 proteins.
Absstract of: WO2025231157A2
The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.
Absstract of: WO2025230087A1
The present invention relates to an attenuated SARS-CoV-2 vaccine strain including nucleocapsid N gene transcriptional repression and a non-structural protein 1 (nsp1) protein mutation, and a use thereof. The attenuated SARS-CoV-2 vaccine strain according to the present invention has excellent safety and efficacy as a vaccine, and thus can be effectively used as an attenuated live vaccine for the prevention of coronavirus disease 2019.
Nº publicación: WO2025230306A1 06/11/2025
Applicant:
GWANGJU INSTITUTE OF SCIENCE AND TECH [KR]
JD BIOSCIENCE INC [KR]
KOREA RESEARCH INSTITUTE OF CHEMICAL TECH [KR]
\uAD11\uC8FC\uACFC\uD559\uAE30\uC220\uC6D0,
\uC8FC\uC2DD\uD68C\uC0AC \uC81C\uC774\uB514\uBC14\uC774\uC624\uC0AC\uC774\uC5B8\uC2A4,
\uD55C\uAD6D\uD654\uD559\uC5F0\uAD6C\uC6D0
Absstract of: WO2025230306A1
The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.
BOPI
Electronic site
